Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPMAURO, Geovanne PedroRIBEIRO NETO, MarioCARVALHO, Heloisa de Andrade2024-04-052024-04-052023REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY, v.28, n.5, p.601-607, 20231507-1367https://observatorio.fm.usp.br/handle/OPI/59222Background: Recurrent diffuse large B-cell lymphoma (DLBCL) is a disease with high mortality. The standard of care involves autologous stem-cell transplantation (ASCT), which is not always feasible. We investigated the impact of radiotherapy as part of the salvage treatment for patients with relapsed disease. Materials and methods: Retrospective study of patients with recurrent DLBCL after chemotherapy and consolidative radiotherapy at a single institution. All patients were included if radiation was part of the first treatment. Results: Of 359 patients assessed between 2010 and 2017, 65 (18.1%) presented a recurrence, but only 62 received further treatment and were included in the study. Mean overall survival was 18.6 months since diagnosis and progression-free survival after first progression (PFS2) was 7.7 months. Patients were divided into two groups according to whether they did (24.8%) or did not (75.8%) receive radiation as part of their salvage treatment. Patients that did not receive R-CHOP (rituximab plus cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone) in the first line were treated more with radiation in the second line (p = 0.02). Six patients with in-field relapse were re-irradiated. Only 4 patients received ASCT as part of their treatment for relapsed disease. There was no difference in outcomes. Conclusion: There is a place for radiotherapy in the treatment of relapsed DLBCL, particularly when patients do not receive ASCT. Radiotherapy is well-tolerated. More trials to assess the role of radiotherapy for these patients are needed.engrestrictedAccessnon-Hodgkin lymphomarefractory lymphomaradiotherapyinvolved-field radiotherapyradiation-therapytransplantationchemotherapyregimensstagechoparticleCopyright VIA MEDICA10.5603/rpor.96866OncologyRadiology, Nuclear Medicine & Medical Imaging2083-4640